Arab Journal of Urology · 2015 · 15 citations · 29 references
MedicineOncologyUrologyMolecular OncologyNeoplasiaTumor ProgressionBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerMalignant NeoplasmsUrothelial CarcinomaBladder Cancer Recurrence BiomarkersHer2 AmplificationHer2 ExpressionImmunohistochemical BiomarkersImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingNon-muscle-invasive Bladder Cancer Therapy
OBJECTIVE: To investigate whether the immunohistochemical expression of p53, p63 and her2/neu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer. PATIENTS AND METHODS: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2/neu immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 36 months in the Urology Department. RESULTS: For tumour grade there was a significant relationship with the overexpression of p53 (P = 0.010), her2 (P = 0.025) and negativity of p63 (P = 0.025). There was no significant relationship between p53 or her2/neu overexpression and tumour stage. However, there was a significant correlation (P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 (P = 0.01), her2/neu (P = 0.025) overexpression and p63 negativity (P = 0.005) and tumour recurrence and progression. CONCLUSION: Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2/neu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies.
29
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Annie Yang, Ronen Schweitzer, Deqin Sun et al. · Nature · 1999 · 2.2K citations
p63 expression profiles in human normal and tumor tissues.
Charles J. Di Como, Marshall Urist, Irina Babayan et al. · PubMed · 2002 · 521 citations
Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer
Marshall Urist, Charles J. Di Como, Ming-Lan Lu et al. · American Journal Of Pathology · 2002 · 258 citations · Full text